Rheumatology Advances in Practice, published by Oxford University Press, is a vital open-access journal dedicated to advancing research and education in the field of rheumatology. With an E-ISSN of 2514-1775 and an impressive open access model established since 2017, this journal facilitates the dissemination of cutting-edge knowledge and innovative practices to a global audience. It has garnered recognition within the academic community, holding a Q3 classification in Rheumatology for 2023, which reflects its contribution to the evolving landscape of rheumatological research. The journal aims to present high-quality, peer-reviewed articles that explore the latest findings, advancements, and clinical applications in rheumatology, making it an essential resource for researchers, healthcare professionals, and students alike. By bridging the gap between research and practice, Rheumatology Advances in Practice plays a significant role in improving the care of patients with rheumatological conditions, promoting evidence-based approaches to clinical challenges.

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.

Lupus Science & Medicine is a leading open-access journal published by the BMJ Publishing Group, dedicated to advancing the understanding and treatment of lupus and related autoimmune diseases. Since its establishment in 2014, the journal has fostered an academic environment for researchers, healthcare professionals, and students, providing a platform for high-quality, evidence-based studies. With a notable impact in the fields of immunology and rheumatology, it currently holds a Q1 ranking in Rheumatology and Medicine (miscellaneous) and Q2 in Immunology, reflecting its significant contribution to these vital areas of medical research. The journal is indexed in Scopus, with a commendable rank in the 67th percentile for Rheumatology, making it a valuable resource for those seeking the latest insights into lupus management and treatment. The journal emphasizes the importance of open access, ensuring that research findings are widely available to enhance global knowledge and collaboration in the fight against lupus.

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

RHEUMATOLOGY, published by Oxford University Press, is a leading journal in the fields of Pharmacology and Rheumatology, recognized for its significant contribution to advancing the understanding and treatment of rheumatic diseases. With an impressive impact factor and ranking within the top quartiles for both medical pharmacology and rheumatology, this journal serves as an essential resource for researchers, clinicians, and healthcare professionals. The journal spans an extensive publication history, with contributions from 1952 to 1995 and from 1998 to 2024, reflecting its enduring commitment to disseminating high-quality research. The Open Access option allows for broader dissemination of knowledge, enhancing the visibility of groundbreaking studies. Positioned in the United Kingdom, RHEUMATOLOGY not only offers valuable insights into the latest therapeutic advancements and clinical guidelines but also fosters collaboration across disciplines, ensuring that practitioners stay at the forefront of innovation in the management of rheumatic conditions.

ARP Rheumatology is a pioneering open-access journal dedicated to the field of rheumatology, published by the esteemed Sociedade Portuguesa Reumatologia. Since its inception in 2022, this journal has aimed to bridge the gap between research and clinical practice, providing a platform for the dissemination of high-quality research, case studies, and reviews that advance the understanding and management of rheumatic diseases. Although currently classified in the Q4 category of rheumatology journals with a Scopus rank of 56/73, our commitment to academic excellence and engagement with our readership is unwavering. Located in Portugal, ARP Rheumatology supports a global community of researchers, professionals, and students by maintaining rigorous peer-review standards and promoting innovative scientific discourse. With accessible content and a focus on the latest advancements in the field, ARP Rheumatology is poised to make a significant impact on the future of rheumatology research and practice.

Pediatric Rheumatology is a leading peer-reviewed open access journal published by BMC, dedicated to disseminating high-quality research in the field of pediatric rheumatology. Since its inception in 2007, the journal has established itself as a vital resource for healthcare professionals, researchers, and students focused on pediatric immunology, rheumatology, and child health, maintaining an impressive Q1 ranking in Pediatrics and Q2 in Immunology and Allergy as well as Rheumatology for 2023. It is recognized for its impact on advancing knowledge and clinical practice, with significant contributions noted in various studies and case reports. With access options that embrace the ethos of open science, all articles published in Pediatric Rheumatology are freely available, promoting collaborative research and discussion among practitioners across the globe. The journal welcomes submissions that encapsulate innovative research, clinical trials, and reviews that address both current challenges and advancements within the pediatric rheumatology landscape.

Reumatologia Clinica is a distinguished journal dedicated to the field of Rheumatology, published by Elsevier España SLU. With its ISSN of 1699-258X and E-ISSN 1885-1398, the journal aims to disseminate pivotal research findings and clinical studies from 2005 to 2024, spotlighting advancements in the understanding and treatment of rheumatic diseases. Based in Barcelona, Spain, it plays a vital role in the academic community, ranking in the Q3 category for Rheumatology as of 2023, with a Scopus ranking of #44 out of 73, placing it in the 40th percentile. Although it operates under a traditional access model, the journal is committed to academic excellence, providing researchers, healthcare professionals, and students with invaluable insights that drive the field forward. Reumatologia Clinica serves as an essential resource for those looking to deepen their knowledge and contribute to the evolving landscape of rheumatologic research.

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.